Sexual Dysfunction in Diabetic Patients: Τhe Role of Advanced Glycation
End Products

Μelpomeni      Peppa; Aspasia      Manta
doi:10.2174/1573399819666230407095522
Abstract

Sexual dysfunction is a common but underestimated disorder of diabetic patients of both genders, entailing specific and complex pathogenesis and severely affecting reproductive health and quality of life. Hyperglycemia, dyslipidemia, hypertension, obesity, aging, and psychological factors underlie its pathogenesis. A large body of evidence indicates that advanced glycation end products and oxidative stress have a distinct impact on the pathogenesis of diabetes and its complications, including hypogonadism, which is closely related to sexual dysfunction. Advanced glycation end products seem to affect sexual function either directly by accumulation in various regions of the reproductive system and/or correlation or indirectly through oxidative stress induction via several mechanisms. They are also involved in the pathogenesis of diabetic complications, which are related to sexual dysfunction. Herein, we review the issue of sexual dysfunction in diabetic males and females, with special emphasis on the impact of advanced glycation end products in the pathogenesis of sexual dysfunction, the relationship of advanced glycation end products with low testosterone levels in diabetic subjects, which account for the proportion of disorder and the available therapeutic interventions.
[1]
Kizilay F, Gali HE, Serefoglu EC. Diabetes and sexuality. Sex Med Rev  2017; 5(1): 45-51.
 [http://dx.doi.org/10.1016/j.sxmr.2016.07.002] [PMID:  27544297]

[2]
Gandhi J, Dagur G, Warren K, et al. The role of diabetes mellitus in sexual and reproductive health: An overview of pathogenesis, evaluation, and management. Curr Diabetes Rev  2017; 13(6): 573-81.
 [PMID:  27875946]

[3]
Avasthi A, Grover S, Bhansali A, et al. Erectile dysfunction in diabetes mellitus contributes to poor quality of life. Int Rev Psychiatry  2011; 23(1): 93-9.
 [http://dx.doi.org/10.3109/09540261.2010.545987] [PMID:  21338304]

[4]
Nappi PRE, Cucinella L, Martella S, Rossi M, Tiranini L, Martini E. Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL). Maturitas  2016; 94: 87-91.
 [http://dx.doi.org/10.1016/j.maturitas.2016.09.013] [PMID:  27823751]

[5]
Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: Current perspectives. Diabetes Metab Syndr Obes  2014; 7: 95-105.
 [PMID:  24623985]

[6]
Shivananda MJ, Rao TSS. Sexual dysfunction in medical practice. Curr Opin Psychiatry  2016; 29(6): 331-5.
 [http://dx.doi.org/10.1097/YCO.0000000000000281] [PMID:  27636599]

[7]
Levin RJ, Both S, Georgiadis J, Kukkonen T, Park K, Yang CC. The physiology of female sexual function and the pathophysiology of female sexual dysfunction (Committee 13A). J Sex Med  2016; 13(5): 733-59.
 [http://dx.doi.org/10.1016/j.jsxm.2016.02.172] [PMID:  27114190]

[8]
McCabe MP, Sharlip ID, Atalla E, et al. Definitions of sexual dysfunctions in women and men: A consensus statement from the fourth international consultation on sexual medicine 2015; J Sex Med  2016; 13(2): 135-43.
 [http://dx.doi.org/10.1016/j.jsxm.2015.12.019] [PMID:  26953828]

[9]
Kamenov ZA. A comprehensive review of erectile dysfunction in men with diabetes. Exp Clin Endocrinol Diabetes  2015; 123(3): 141-58.
 [PMID:  25502583]

[10]
Giraldi A, Kristensen E. Sexual dysfunction in women with diabetes mellitus. J Sex Res  2010; 47(2-3): 199-211.
 [http://dx.doi.org/10.1080/00224491003632834] [PMID:  20358461]

[11]
Bargiota A, Dimitropoulos K, Tzortzis V, Koukoulis G. Sexual dysfunction in diabetic women. Hormones  2011; 10(3): 196-206.
 [http://dx.doi.org/10.14310/horm.2002.1309] [PMID:  22001130]

[12]
Amidu N, Owiredu WKBA, Alidu H, Sarpong C, Gyasi-Sarpong CK, Quaye L. Association between metabolic syndrome and sexual dysfunction among men with clinically diagnosed diabetes. Diabetol Metab Syndr  2013; 5(1): 42.
 [http://dx.doi.org/10.1186/1758-5996-5-42] [PMID:  23895401]

[13]
Trompeter SE, Bettencourt R, Barrett-Connor E. Metabolic syndrome and sexual function in postmenopausal women. Am J Med  2016; 129(12): 1270-1277.e1.
 [http://dx.doi.org/10.1016/j.amjmed.2016.03.039] [PMID:  27132570]

[14]
Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: Epidemiology, pathophysiology and management. J Diabetes Complications  2011; 25(2): 129-36.
 [http://dx.doi.org/10.1016/j.jdiacomp.2010.03.003] [PMID:  20462773]

[15]
Li Y, Zhang M, Liu X, et al. Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes. Andrology  2017; 5(4): 739-43.
 [http://dx.doi.org/10.1111/andr.12360] [PMID:  28470687]

[16]
Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum testosterone levels in male hypogonadism: Why and when to check-A review. Int J Clin Pract  2017; 71(11): e12995.
 [http://dx.doi.org/10.1111/ijcp.12995] [PMID:  28980739]

[17]
Cai M, Cui R, Yang P, et al. Incidence and risk factors of hypogonadism in male patients with latent autoimmune diabetes and classic type 2 diabetes. Front Endocrinol  2021; 12: 675525.
 [http://dx.doi.org/10.3389/fendo.2021.675525] [PMID:  34135863]

[18]
George JT, Millar RP, Anderson RA. Hypothesis: Kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology  2010; 91(4): 302-7.
 [http://dx.doi.org/10.1159/000299767] [PMID:  20628262]

[19]
Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol  2009; 5(12): 673-81.
 [http://dx.doi.org/10.1038/nrendo.2009.212] [PMID:  19859074]

[20]
Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab  2006; 91(9): 3324-8.
 [http://dx.doi.org/10.1210/jc.2006-0462] [PMID:  16787981]

[21]
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol  2011; 11(2): 85-97.
 [http://dx.doi.org/10.1038/nri2921] [PMID:  21252989]

[22]
Burke JP, Jacobson DJ, McGree ME, et al. Diabetes and sexual dysfunction: Results from the Olmsted County study of urinary symptoms and health status among men. J Urol  2007; 177(4): 1438-42.
 [http://dx.doi.org/10.1016/j.juro.2006.11.059] [PMID:  17382749]

[23]
Van Cauwenberghe J, Enzlin P, Nefs G, et al. Prevalence of and risk factors for sexual dysfunctions in adults with type 1 or type 2 diabetes: Results from Diabetes MILES ‐ Flanders. Diabet Med  2022; 39(1): e14676.
 [http://dx.doi.org/10.1111/dme.14676] [PMID:  34432909]

[24]
Vickers MA, Wright EA. Erectile dysfunction in the patient with diabetes mellitus. Am J Manag Care  2004; 10(S1): S3-S11.
 [PMID:  14974584]

[25]
Hackett G, Krychman M, Baldwin D, et al. Coronary heart disease, diabetes, and sexuality in men. J Sex Med  2016; 13(6): 887-904.
 [http://dx.doi.org/10.1016/j.jsxm.2016.01.023] [PMID:  27215685]

[26]
Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med  2009; 6(5): 1232-47.
 [http://dx.doi.org/10.1111/j.1743-6109.2008.01168.x] [PMID:  19210706]

[27]
Jin M, Yuan S, Wang B, Yi L, Wang C. Association between prediabetes and erectile dysfunction: A meta-analysis. Front Endocrinol  2022; 12: 733434.
 [http://dx.doi.org/10.3389/fendo.2021.733434] [PMID:  35082752]

[28]
Podlasek CA, Mulhall J, Davies K, et al. Translational perspective on the role of testosterone in sexual function and dysfunction. J Sex Med  2016; 13(8): 1183-98.
 [http://dx.doi.org/10.1016/j.jsxm.2016.06.004] [PMID:  27436075]

[29]
Gan EH, Pattman S, H S Pearce S, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol  2013; 79(4): 564-70.
 [http://dx.doi.org/10.1111/cen.12178] [PMID:  23480258]

[30]
Corona G, Vena W, Pizzocaro A, Vignozzi L, Sforza A, Maggi M. Testosterone therapy in diabetes and pre‐diabetes. Andrology  2023; 11(2): 204-14.
 [http://dx.doi.org/10.1111/andr.13367] [PMID:  36542412]

[31]
Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab  2004; 89(11): 5462-8.
 [http://dx.doi.org/10.1210/jc.2004-0804] [PMID:  15531498]

[32]
La Vignera S, Condorelli RA, Cannarella R, et al. Urogenital infections in patients with diabetes mellitus: Beyond the conventional aspects. Int J Immunopathol Pharmacol  2019; 33.
 [http://dx.doi.org/10.1177/2058738419866582] [PMID:  32031031]

[33]
Bromage SJ, Crump A, Pearce I. Phimosis as a presenting feature of diabetes. BJU Int  2008; 101(3): 338-40.
 [http://dx.doi.org/10.1111/j.1464-410X.2007.07274.x] [PMID:  18005214]

[34]
El-Sakka A, Tayeb KA. Peyronie’s disease in diabetic patients being screened for erectile dysfunction. J Urol  2005; 174(3): 1026-30.
 [http://dx.doi.org/10.1097/01.ju.0000170231.51306.32] [PMID:  16094040]

[35]
Navriya SC, Ravikant , Panwar P, Tendulkar P, Khapre M. Major sexual function domains affected in the diabetic females: A cross-sectional study from North India. Indian J Endocrinol Metab  2022; 26(5): 478-82.
 [http://dx.doi.org/10.4103/ijem.ijem_68_22] [PMID:  36618528]

[36]
Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: A systematic review and meta-analysis. J Sex Med  2013; 10(4): 1044-51.
 [http://dx.doi.org/10.1111/jsm.12065] [PMID:  23347454]

[37]
Maiorino MI, Bellastella G, Castaldo F, Petrizzo M, Giugliano D, Esposito K. Sexual function in young women with type 1 diabetes: The METRO study. J Endocrinol Invest  2017; 40(2): 169-77.
 [http://dx.doi.org/10.1007/s40618-016-0542-5] [PMID:  27613610]

[38]
Dhatariya KK. Sexual dysfunction in women with type 1 diabetes: Long-term findings from the DCCT/EDIC study cohort: response to Enzlin et al. Diabetes Care  2010; 33(1): e19.
 [http://dx.doi.org/10.2337/dc09-0910] [PMID:  20040669]

[39]
Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res  2010; 22(3): 179-84.
 [http://dx.doi.org/10.1038/ijir.2010.6] [PMID:  20376056]

[40]
Yenice MG, Danacıoğlu YO, Mert M, et al. Evaluation of factors affecting sexual dysfunction in female patients with diabetes mellitus. Arch Endocrinol Metab  2020; 64(3): 319-25.
 [http://dx.doi.org/10.20945/2359-3997000000238] [PMID:  32267365]

[41]
Haugstvedt A, Jørgensen J, Strandberg RB, et al. Sexual dysfunction in women with type 1 diabetes in Norway: A cross‐sectional study on the prevalence and associations with physical and psychosocial complications. Diabet Med  2022; 39(1): e14704.
 [http://dx.doi.org/10.1111/dme.14704] [PMID:  34596251]

[42]
Buskoven MEH, Kjørholt EKH, Strandberg RB, Søfteland E, Haugstvedt A. Sexual dysfunction in women with type 1 diabetes in Norway: A qualitative study of women’s experiences. Diabet Med  2022; 39(7): e14856.
 [http://dx.doi.org/10.1111/dme.14856] [PMID:  35460298]

[43]
Zamponi V, Mazzilli R, Bitterman O, et al. Association between type 1 diabetes and female sexual dysfunction. BMC Womens Health  2020; 20(1): 73.
 [http://dx.doi.org/10.1186/s12905-020-00939-1] [PMID:  32299459]

[44]
Salonia A, Lanzi R, Scavini M, et al. Sexual function and endocrine profile in fertile women with type 1 diabetes. Diabetes Care  2006; 29(2): 312-6.
 [http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1067] [PMID:  16443879]

[45]
Bąk E, Młynarska A, Sternal D, Kadłubowska M, Marcisz-Dyla E, Marcisz C. Sexual function and sexual quality of life in premenopausal women with controlled type 1 and 2 diabetes—preliminary study. Int J Environ Res Public Health  2021; 18(5): 2536.
 [http://dx.doi.org/10.3390/ijerph18052536] [PMID:  33806371]

[46]
Loh HH, Yee A, Loh HS, Kanagasundram S, Francis B, Lim LL. Sexual dysfunction in polycystic ovary syndrome: A systematic review and meta-analysis. Hormones  2020; 19(3): 413-23.
 [http://dx.doi.org/10.1007/s42000-020-00210-0] [PMID:  32462512]

[47]
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology  1997; 49(6): 822-30.
 [http://dx.doi.org/10.1016/S0090-4295(97)00238-0] [PMID:  9187685]

[48]
Maseroli E, Fanni E, Fambrini M, et al. Bringing the body of the iceberg to the surface: the Female Sexual Dysfunction Index-6 (FSDI-6) in the screening of female sexual dysfunction. J Endocrinol Invest  2016; 39(4): 401-9.
 [http://dx.doi.org/10.1007/s40618-015-0378-4] [PMID:  26335300]

[49]
Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl  2008; 30(1): 1-9.
 [http://dx.doi.org/10.2164/jandrol.108.006486] [PMID:  18772485]

[50]
Reid D, Glass CA, Evans CM, Turner S. Screening impotence by home nocturnal tumescence self-monitoring. Br J Clin Psychol  1990; 29(4): 439-41.
 [http://dx.doi.org/10.1111/j.2044-8260.1990.tb00910.x] [PMID:  2289082]

[51]
Faubion SS, Rullo JE. Sexual dysfunction in women: A practical approach. Am Fam Physician  2015; 92(4): 281-8.
 [PMID:  26280233]

[52]
Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci  2002; 99(24): 15596-601.
 [http://dx.doi.org/10.1073/pnas.242407999] [PMID:  12429856]

[53]
Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: A General overview. Hormones  2005; 4(1): 28-37.
 [http://dx.doi.org/10.14310/horm.2002.11140] [PMID:  16574629]

[54]
Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep  2004; 4(1): 31-6.
 [http://dx.doi.org/10.1007/s11892-004-0008-6] [PMID:  14764277]

[55]
Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci  2005; 1043(1): 461-6.
 [http://dx.doi.org/10.1196/annals.1333.052] [PMID:  16037267]

[56]
Cai W, Gao Q, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med  2002; 8(7): 337-46.
 [http://dx.doi.org/10.1007/BF03402014] [PMID:  12393931]

[57]
Tahara N, Imaizumi T, Takeuchi M, Yamagishi S. Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid Med Cell Longev  2010; 3(4): 262-5.
 [http://dx.doi.org/10.4161/oxim.3.4.12734] [PMID:  20972372]

[58]
Zhao YT, Qi YW, Hu CY, Chen SH, Liu Y. Advanced glycation end products inhibit testosterone secretion by rat Leydig cells by inducing oxidative stress and endoplasmic reticulum stress. Int J Mol Med  2016; 38(2): 659-65.59.
 [http://dx.doi.org/10.3892/ijmm.2016.2645]

[59]
Chatzigeorgiou A, Kandaraki E, Piperi C, et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol  2013; 218(3): 331-7.
 [http://dx.doi.org/10.1530/JOE-13-0175] [PMID:  23823020]

[60]
Diamanti-Kandarakis E, Papalou O, Kandaraki EA, Kassi G. MECHANISMS IN ENDOCRINOLOGY: Nutrition as a mediator of oxidative stress in metabolic and reproductive disorders in women. Eur J Endocrinol  2017; 176(2): R79-99.
 [http://dx.doi.org/10.1530/EJE-16-0616] [PMID:  27678478]

[61]
Diamanti-Kandarakis E, Lambrinoudaki I, Economou F, et al. Androgens associated with advanced glycation end-products in postmenopausal women. Menopause  2010; 17(6): 1182-7.
 [http://dx.doi.org/10.1097/gme.0b013e3181e170af] [PMID:  20647960]

[62]
Neves D. Advanced glycation end-products: A common pathway in diabetes and age-related erectile dysfunction. Free Radic Res  2013; 47(S1): 49-69.
 [http://dx.doi.org/10.3109/10715762.2013.821701]

[63]
Usta MF, Kendirci M, Gur S, et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: Preventive versus curative treatment. J Sex Med  2006; 3(2): 242-52.
 [http://dx.doi.org/10.1111/j.1743-6109.2006.00217.x] [PMID:  16490017]

[64]
Cartledge JJ, Eardley I, Morrison JFB. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int  2001; 87(4): 402-7.
 [http://dx.doi.org/10.1046/j.1464-410x.2001.00067.x] [PMID:  11251537]

[65]
Jiaan DB, Seftel AD, Fogarty J, et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol  1995; 13(6): 369-75.
 [http://dx.doi.org/10.1007/BF00191219] [PMID:  9116757]

[66]
Emanuele E, Bertona M. Endogenous secretory RAGE as a potential biochemical screening tool for erectile dysfunction. Med Hypotheses  2006; 67(3): 668-9.
 [http://dx.doi.org/10.1016/j.mehy.2006.04.023] [PMID:  16750897]

[67]
Mallidis C, Agbaje I, Rogers D, et al. Distribution of the receptor for advanced glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus. Hum Reprod  2007; 22(8): 2169-77.
 [http://dx.doi.org/10.1093/humrep/dem156] [PMID:  17588956]

[68]
Mallidis C, Agbaje IM, Rogers DA, et al. Advanced glycation end products accumulate in the reproductive tract of men with diabetes. Int J Androl  2009; 32(4): 295-305.
 [http://dx.doi.org/10.1111/j.1365-2605.2007.00849.x] [PMID:  18217985]

[69]
Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition, and possible effect through inos or enos. Urology  1997; 50(6): 1016-26.
 [http://dx.doi.org/10.1016/S0090-4295(97)00512-8] [PMID:  9426743]

[70]
Kouidrat Y, Zaitouni A, Amad A, et al. Skin autofluorescence (a marker for advanced glycation end products) and erectile dysfunction in diabetes. J Diabetes Complications  2017; 31(1): 108-13.
 [http://dx.doi.org/10.1016/j.jdiacomp.2016.10.026] [PMID:  27847146]

[71]
Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia  2004; 47(11): 1914-23.
 [http://dx.doi.org/10.1007/s00125-004-1549-6] [PMID:  15599697]

[72]
Karimi J, Goodarzi MT, Tavilani H, Khodadadi I, Amiri I. Increased receptor for advanced glycation end products in spermatozoa of diabetic men and its association with sperm nuclear DNA fragmentation. Andrologia  2012; 44(S1): 280-6.
 [http://dx.doi.org/10.1111/j.1439-0272.2011.01178.x]

[73]
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clin Exp Med  2011; 11(2): 131-5.
 [http://dx.doi.org/10.1007/s10238-010-0109-2] [PMID:  20803229]

[74]
Usta MF, Bivalacqua TJ, Koksal IT, Toptas B, Surmen S, Hellstrom WJG. The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU Int  2004; 94(3): 429-32.
 [http://dx.doi.org/10.1111/j.1464-410X.2004.04937.x] [PMID:  15291881]

[75]
Orman D, Vardi N, Ates B, Taslidere E, Elbe H. Aminoguanidine mitigates apoptosis, testicular seminiferous tubules damage, and oxidative stress in streptozotocin-induced diabetic rats. Tissue Cell  2015; 47(3): 284-90.
 [http://dx.doi.org/10.1016/j.tice.2015.03.006] [PMID:  25862575]

[76]
Wang L, Tian W, Uwais Z, et al. AGE-breaker ALT-711 plus insulin could restore erectile function in streptozocin-induced type 1 diabetic rats. J Sex Med  2014; 11(6): 1452-62.
 [http://dx.doi.org/10.1111/jsm.12533] [PMID:  24766706]

[77]
Gurbuz N, Sagdic G, Sanli A, et al. Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. Int J Impot Res  2012; 24(3): 114-21.
 [http://dx.doi.org/10.1038/ijir.2011.54] [PMID:  22205245]

[78]
Gurbuz N, Gurkan R, Ender Caylan A, Surmen Usta S, Usta MF. The therapeutic effect of ALT-711 on erectile function in rats treated with high-level AGEs (advanced glycation end products) containing diet. Int J Impot Res  2022; 34(2): 222-8.
 [http://dx.doi.org/10.1038/s41443-021-00417-8] [PMID:  33712808]

[79]
Goswami SK, Gangadarappa SK, Vishwanath M, et al. Antioxidant potential and ability of phloroglucinol to decrease formation of advanced glycation end products increase efficacy of sildenafil in diabetes-induced sexual dysfunction of rats. Sex Med  2016; 4(2): e106-14.
 [http://dx.doi.org/10.1016/j.esxm.2015.12.002] [PMID:  26831914]

[80]
Perez Gutierrez RM. Inhibition of advanced glycation end-product formation by Origanum majorana L in vitro and in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med 2012.

[81]
Goswami SK, Vishwanath M, Gangadarappa S, Razdan R, Inamdar MN. Efficacy of ellagic acid and sildenafil in diabetes-induced sexual dysfunction. Pharmacogn Mag  2014; (10): S581-7.
 [http://dx.doi.org/10.4103/0973-1296.139790]

[82]
Goswami SK, Inamdar MN, Jamwal R, Dethe S. Efficacy of Cinnamomum cassia Blume. in age induced sexual dysfunction of rats. J Young Pharm  2013; 5(4): 148-53.
 [http://dx.doi.org/10.1016/j.jyp.2013.11.001] [PMID:  24563594]

[83]
Wang L, Xu Y, Li H, et al. Antioxidant icariside II combined with insulin restores erectile function in streptozotocin‐induced type 1 diabetic rats. J Cell Mol Med  2015; 19(5): 960-9.
 [http://dx.doi.org/10.1111/jcmm.12480] [PMID:  25781208]

[84]
Chen Y, Wu Y, Gan X, et al. Iridoid glycoside from Cornus officinalis ameliorated diabetes mellitus-induced testicular damage in male rats: Involvement of suppression of the AGEs/RAGE/p38 MAPK signaling pathway. J Ethnopharmacol  2016; 194: 850-60.
 [http://dx.doi.org/10.1016/j.jep.2016.10.079] [PMID:  27989876]

[85]
Brock G, Harper W. Erectile dysfunction. Can J Diabetes  2013; 37(S1)
 [http://dx.doi.org/10.1016/j.jcjd.2013.01.041]

[86]
Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab  2004; 89(11): 5429-34.
 [http://dx.doi.org/10.1210/jc.2004-0897] [PMID:  15531493]

[87]
Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA  2013; 310(17): 1829-36.
 [http://dx.doi.org/10.1001/jama.2013.280386] [PMID:  24193080]

[88]
Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol  2005; 63(4): 381-94.
 [http://dx.doi.org/10.1111/j.1365-2265.2005.02350.x] [PMID:  16181230]

[89]
Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab  2012; 97(6): 2050-8.
 [http://dx.doi.org/10.1210/jc.2011-2591] [PMID:  22496507]

[90]
Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol  2013; 169(6): 725-33.
 [http://dx.doi.org/10.1530/EJE-13-0321] [PMID:  23999642]

[91]
Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One  2014; 9(1): e85805.
 [http://dx.doi.org/10.1371/journal.pone.0085805] [PMID:  24489673]

[92]
Thirumalai A, Anawalt BD. Relationships between endogenous and exogenous testosterone and cardiovascular disease in men. Rev Endocr Metab Disord  2022; 23(6): 1305-22.
 [http://dx.doi.org/10.1007/s11154-022-09752-7] [PMID:  36219323]

[93]
Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): A randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol  2021; 9(1): 32-45.
 [http://dx.doi.org/10.1016/S2213-8587(20)30367-3] [PMID:  33338415]

[94]
Cignarelli A, Genchi VA, D’Oria R, et al. Role of glucose-lowering medications in erectile dysfunction. J Clin Med  2021; 10(11): 2501.
 [http://dx.doi.org/10.3390/jcm10112501] [PMID:  34198786]

[95]
Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes Metab Res Rev  2022; 38(2): e3494.
 [http://dx.doi.org/10.1002/dmrr.3494] [PMID:  34514697]

[96]
Bajaj HS, Gerstein HC, Rao-Melacini P, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol  2021; 9(8): 484-90.
 [http://dx.doi.org/10.1016/S2213-8587(21)00115-7] [PMID:  34153269]

[97]
Khoo J, Piantadosi C, Duncan R, et al. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med  2011; 8(10): 2868-75.
 [http://dx.doi.org/10.1111/j.1743-6109.2011.02417.x] [PMID:  21819545]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1573399819666230407095522	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417
Current Diabetes Reviews

Sexual Dysfunction in Diabetic Patients: Τhe Role of Advanced Glycation End Products

Abstract Play Pause

Related Journals

Related Books

Abstract
